Synapsoft logo
AI Insights from Disclosures
Searching...
OliX Pharmaceuticals, Inc. 226950
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
OliX Pharmaceuticals, Inc. is a new drug development company that develops treatments for diseases that existing therapeutics find difficult to address, based on its RNA interference (RNAi) platform technology. RNA interference technology is a realized technology among oligonucleotide therapeutics, called the third-generation platform technology following small-molecule compounds and antibody therapeutics, which are existing new drug development platforms, and it can efficiently suppress the gene expression and protein production that cause disease.
Representative Director Lee Donggi
Founded February 26, 2010
Corporation Type KOSDAQ
Industry Classification Research and experimental development on medical sciences and pharmacy
Corporate number 13581-0177957
Business number 124-86-90516
Phone Number 031-779-8400
Fax Number 031-779-8499
Company Address 953 Daewangpangyo-ro, Sujeong-gu, Seongnam-si, Gyeonggi-do
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant